Roberto Bolli1, Joshua M Hare2, Timothy D Henry3, Carrie G Lenneman1, Keith L March4, Kathy Miller4, Carl J Pepine5, Emerson C Perin6, Jay H Traverse7, James T Willerson6, Phillip C Yang8, Adrian P Gee9, João A Lima10, Lem Moyé11, Rachel W Vojvodic12, Shelly L Sayre12, Judy Bettencourt12, Michelle Cohen12, Ray F Ebert13, Robert D Simari14. 1. University of Louisville, Louisville, KY. 2. University of Miami Miller School of Medicine, Miami, Florida. 3. Cedars-Sinai Heart Institute, Los Angeles, California. 4. Indiana University School of Medicine, Indianapolis, Indiana. 5. University of Florida School of Medicine, Gainesville, Florida. 6. Texas Heart Institute, CHI St. Luke's Health, Houston, TX. 7. Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital, Minneapolis, MN. 8. Stanford University School of Medicine, Stanford, California. 9. Baylor College of Medicine, Houston, TX. 10. Johns Hopkins University, Baltimore, MD. 11. UT Health School of Public Health, Houston, TX. Electronic address: lemmoye@msn.com. 12. UT Health School of Public Health, Houston, TX. 13. NIH, National Heart, Lung, and Blood Institute, Bethesda, MD. 14. University of Kansas School of Medicine, Kansas City, Kansas.
Abstract
OBJECTIVES:SENECA (StEm cell iNjECtion in cAncer survivors) is a phase I, randomized, double-blind, placebo-controlled study to evaluate the safety and feasibility of delivering allogeneic mesenchymal stromal cells (allo-MSCs) transendocardially in subjects with anthracycline-induced cardiomyopathy (AIC). BACKGROUND: AIC is an incurable and often fatal syndrome, with a prognosis worse than that of ischemic or nonischemic cardiomyopathy. Recently, cell therapy with MSCs has emerged as a promising new approach to repair damaged myocardium. METHODS: The study population is 36 cancer survivors with a diagnosis of AIC, left ventricular (LV) ejection fraction ≤40%, and symptoms of heart failure (NYHA class II-III) on optimally-tolerated medical therapy. Subjects must be clinically free of cancer for at least two years with a ≤ 30% estimated five-year risk of recurrence. The first six subjects participated in an open-label, lead-in phase and received 100 million allo-MSCs; the remaining 30 will be randomized 1:1 to receive allo-MSCs or vehicle via 20 transendocardial injections. Efficacy measures (obtained at baseline, 6 months, and 12 months) include MRI evaluation of LV function, LV volumes, fibrosis, and scar burden; assessment of exercise tolerance (six-minute walk test) and quality of life (Minnesota Living with Heart Failure Questionnaire); clinical outcomes (MACE and cumulative days alive and out of hospital); and biomarkers of heart failure (NT-proBNP). CONCLUSIONS: This is the first clinical trial using direct cardiac injection of cells for the treatment of AIC. If administration of allo-MSCs is found feasible and safe, SENECA will pave the way for larger phase II/III studies with therapeutic efficacy as the primary outcome.
RCT Entities:
OBJECTIVES: SENECA (StEm cell iNjECtion in cAncer survivors) is a phase I, randomized, double-blind, placebo-controlled study to evaluate the safety and feasibility of delivering allogeneic mesenchymal stromal cells (allo-MSCs) transendocardially in subjects with anthracycline-induced cardiomyopathy (AIC). BACKGROUND:AIC is an incurable and often fatal syndrome, with a prognosis worse than that of ischemic or nonischemic cardiomyopathy. Recently, cell therapy with MSCs has emerged as a promising new approach to repair damaged myocardium. METHODS: The study population is 36 cancer survivors with a diagnosis of AIC, left ventricular (LV) ejection fraction ≤40%, and symptoms of heart failure (NYHA class II-III) on optimally-tolerated medical therapy. Subjects must be clinically free of cancer for at least two years with a ≤ 30% estimated five-year risk of recurrence. The first six subjects participated in an open-label, lead-in phase and received 100 million allo-MSCs; the remaining 30 will be randomized 1:1 to receive allo-MSCs or vehicle via 20 transendocardial injections. Efficacy measures (obtained at baseline, 6 months, and 12 months) include MRI evaluation of LV function, LV volumes, fibrosis, and scar burden; assessment of exercise tolerance (six-minute walk test) and quality of life (Minnesota Living with Heart Failure Questionnaire); clinical outcomes (MACE and cumulative days alive and out of hospital); and biomarkers of heart failure (NT-proBNP). CONCLUSIONS: This is the first clinical trial using direct cardiac injection of cells for the treatment of AIC. If administration of allo-MSCs is found feasible and safe, SENECA will pave the way for larger phase II/III studies with therapeutic efficacy as the primary outcome.
Authors: Konstantinos E Hatzistergos; Henry Quevedo; Behzad N Oskouei; Qinghua Hu; Gary S Feigenbaum; Irene S Margitich; Ramesh Mazhari; Andrew J Boyle; Juan P Zambrano; Jose E Rodriguez; Raul Dulce; Pradip M Pattany; David Valdes; Concepcion Revilla; Alan W Heldman; Ian McNiece; Joshua M Hare Journal: Circ Res Date: 2010-07-29 Impact factor: 17.367
Authors: Vasileios Karantalis; Viky Y Suncion-Loescher; Luiza Bagno; Samuel Golpanian; Ariel Wolf; Cristina Sanina; Courtney Premer; Anthony J Kanelidis; Frederic McCall; Bo Wang; Wayne Balkan; Jose Rodriguez; Marcos Rosado; Azorides Morales; Konstantinos Hatzistergos; Makoto Natsumeda; Irene Margitich; Ivonne Hernandez Schulman; Samirah A Gomes; Muzammil Mushtaq; Darcy L DiFede; Joel E Fishman; Pradip Pattany; Juan Pablo Zambrano; Alan W Heldman; Joshua M Hare Journal: J Am Coll Cardiol Date: 2015-11-03 Impact factor: 24.094
Authors: Viky Y Suncion; Eduard Ghersin; Joel E Fishman; Juan Pablo Zambrano; Vasileios Karantalis; Nicole Mandel; Katarina H Nelson; Gary Gerstenblith; Darcy L DiFede Velazquez; Elayne Breton; Kranthi Sitammagari; Ivonne H Schulman; Sabrina N Taldone; Adam R Williams; Cristina Sanina; Peter V Johnston; Jeffrey Brinker; Peter Altman; Muzammil Mushtaq; Barry Trachtenberg; Adam M Mendizabal; Melissa Tracy; Jose Da Silva; Ian K McNiece; Alberto C Lardo; Richard T George; Joshua M Hare; Alan W Heldman Journal: Circ Res Date: 2014-01-21 Impact factor: 17.367
Authors: Henry C Quevedo; Konstantinos E Hatzistergos; Behzad N Oskouei; Gary S Feigenbaum; Jose E Rodriguez; David Valdes; Pradip M Pattany; Juan P Zambrano; Qinghua Hu; Ian McNiece; Alan W Heldman; Joshua M Hare Journal: Proc Natl Acad Sci U S A Date: 2009-08-05 Impact factor: 11.205
Authors: Guilherme V Silva; Silvio Litovsky; Joao A R Assad; Andre L S Sousa; Bradley J Martin; Deborah Vela; Stephanie C Coulter; Jing Lin; Judy Ober; William K Vaughn; Rodrigo V C Branco; Edie M Oliveira; Rumin He; Yong-Jian Geng; James T Willerson; Emerson C Perin Journal: Circulation Date: 2005-01-10 Impact factor: 29.690
Authors: Diptiman Chanda; Tatyana Isayeva; Sanjay Kumar; Jonathan A Hensel; Anandi Sawant; Girish Ramaswamy; Gene P Siegal; Matthew S Beatty; Selvarangan Ponnazhagan Journal: Clin Cancer Res Date: 2009-11-17 Impact factor: 12.531
Authors: Daniel A Mulrooney; Mark W Yeazel; Toana Kawashima; Ann C Mertens; Pauline Mitby; Marilyn Stovall; Sarah S Donaldson; Daniel M Green; Charles A Sklar; Leslie L Robison; Wendy M Leisenring Journal: BMJ Date: 2009-12-08
Authors: Andrew E Moran; Mohammad H Forouzanfar; Gregory A Roth; George A Mensah; Majid Ezzati; Abraham Flaxman; Christopher J L Murray; Mohsen Naghavi Journal: Circulation Date: 2014-02-26 Impact factor: 29.690
Authors: Alexander Rühle; Ramon Lopez Perez; Bingwen Zou; Anca-Ligia Grosu; Peter E Huber; Nils H Nicolay Journal: Stem Cell Rev Rep Date: 2019-06 Impact factor: 5.739